Letter to the editor. Re: Cost-effectiveness analysis of disease modifying drugs (-interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. Sánchez-de la Rosa R, Sabater E, Casado MA, Arroyo R. JME 2012;15(3):424–33.
| Autor: | Granda ÁS, Jurado LG, Sánchez CP |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of medical economics [J Med Econ] 2012; Vol. 15 (6), pp. 1051-2; author reply 1052-3. Date of Electronic Publication: 2012 May 24. |
| DOI: | 10.3111/13696998.2012.691928 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|